The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2024 | Improving treatment for patients with TP53-mutated myeloid malignancies
David Sallman, MD, Moffitt Cancer Center, Tampa, FL, provides an update on therapies for TP53-mutated acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Trials with eprenetapopt (APR-246) and magrolimab have been unsuccessful, leaving frontline treatment for these high-risk patients an unmet need. Ongoing Phase III trials are investigating venetoclax (VERONA; NCT04401748) and tamibarotene. Additionally, novel combinations, new anti-CD47 agents, and weekly dosing schedules are being explored to improve outcomes. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
